

BIO-TECHNE Corp
 Form 4
 August 22, 2016

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Hippel James

(Last) (First) (Middle)
 614 MCKINLEY PLACE N.E.
 (Street)

MINNEAPOLIS, MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction (Month/Day/Year)
 08/18/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 Chief Financial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock				(A) or (D) Price	3,879 ⁽¹⁾	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: BIO-TECHNE Corp - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Stock Option (Right to Buy)	\$ 86.25					(2) 04/01/2021	Common Stock 25,000
Stock Option (Right to Buy)	\$ 86.25					(3) 04/01/2021	Common Stock 10,000
Stock Option (Right to Buy)	\$ 94.35					(4) 08/12/2021	Common Stock 35,000
Stock Option (Right to Buy)	\$ 108.49					(5) 08/07/2022	Common Stock 25,000
Stock Option (Right to Buy)	\$ 108.49					(7) 08/07/2022	Common Stock 18,750
Restricted Stock Unit	(6)					(7) (7)	Common Stock 3,000
Stock Option (Right to Buy)	\$ 106.59	08/18/2016		A	40,533	(8) 08/18/2023	Common Stock 40,533
Stock Option (Right to Buy)	\$ 106.59	08/18/2016		A	30,400	(9) 08/18/2023	Common Stock 30,400
Restricted Stock Unit	(6)	08/18/2016		A	4,925	(9) (9)	Common Stock 4,925

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hippel James 614 MCKINLEY PLACE N.E. MINNEAPOLIS, MN 55413			Chief Financial Officer	

Signatures

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed.

08/22/2016

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 1,667 shares of restricted stock units that vest on 3/31/17.
- (2) 6,250 shares vest on each of 4/1/15, 4/1/16, 4/1/17 and 4/1/18.
- (3) Vests in full or in part if certain performance goals are achieved.
- (4) 8,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.
- (5) 6,250 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- (6) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (7) Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (8) Vests 10,134 shares on 8/18/17, and 10,133 shares on each of 8/18/18, 8/18/19 and 8/18/20.
- (9) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.